Article
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
British journal of cancer - 25 Jun 2013
Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis C M, Harper P, Maisey N, Ross P, Sanderson J D, Marinaki A M
Abstract excerpt
BACKGROUND: Fluoropyrimidine drugs are extensively used for the treatment of solid cancers. However, adverse drug reactions are a major clinical problem, often necessitating treatment discontinuation. The aim of this study was to identify pharmacogenetic markers predicting fluoropyrimidine toxicity. METHODS: Toxicity in the first four cycles of 5-fluorouracil or capecitabine-based chemotherapy were recorded for a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.